Regulators should expand the types of medical professionals who can prescribe COVID-19 drugs.
The Inflation Reduction Act aims to constrain rapidly increasing drug prices in the United States.
Scholars examine the effectiveness of the contentious 340B Drug Pricing Program.
The collaboration between pharmaceutical giants puts antitrust law at risk.
Experts consider how regulators can make drugs affordable without hindering research and development.
The permissive drug approval process enabled by the 21st Century Cures Act may cause public health problems.